1. Home
  2. NAD vs CELC Comparison

NAD vs CELC Comparison

Compare NAD & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NAD
  • CELC
  • Stock Information
  • Founded
  • NAD 1999
  • CELC 2011
  • Country
  • NAD United States
  • CELC United States
  • Employees
  • NAD N/A
  • CELC N/A
  • Industry
  • NAD Investment Managers
  • CELC Medical Specialities
  • Sector
  • NAD Finance
  • CELC Health Care
  • Exchange
  • NAD Nasdaq
  • CELC Nasdaq
  • Market Cap
  • NAD 2.8B
  • CELC 3.1B
  • IPO Year
  • NAD N/A
  • CELC 2017
  • Fundamental
  • Price
  • NAD $11.98
  • CELC $100.23
  • Analyst Decision
  • NAD
  • CELC Strong Buy
  • Analyst Count
  • NAD 0
  • CELC 7
  • Target Price
  • NAD N/A
  • CELC $95.29
  • AVG Volume (30 Days)
  • NAD 595.7K
  • CELC 916.2K
  • Earning Date
  • NAD 01-01-0001
  • CELC 11-12-2025
  • Dividend Yield
  • NAD 4.35%
  • CELC N/A
  • EPS Growth
  • NAD N/A
  • CELC N/A
  • EPS
  • NAD N/A
  • CELC N/A
  • Revenue
  • NAD N/A
  • CELC N/A
  • Revenue This Year
  • NAD N/A
  • CELC N/A
  • Revenue Next Year
  • NAD N/A
  • CELC N/A
  • P/E Ratio
  • NAD N/A
  • CELC N/A
  • Revenue Growth
  • NAD N/A
  • CELC N/A
  • 52 Week Low
  • NAD $9.56
  • CELC $7.58
  • 52 Week High
  • NAD $11.64
  • CELC $103.06
  • Technical
  • Relative Strength Index (RSI)
  • NAD 55.98
  • CELC 78.25
  • Support Level
  • NAD $11.89
  • CELC $92.10
  • Resistance Level
  • NAD $12.03
  • CELC $103.06
  • Average True Range (ATR)
  • NAD 0.09
  • CELC 5.52
  • MACD
  • NAD -0.01
  • CELC 0.74
  • Stochastic Oscillator
  • NAD 52.70
  • CELC 90.84

About NAD Nuveen Quality Municipal Income Fund

Nuveen Quality Municipal Income Fund is a diversified, closed-end management investment company. Its investment objective is to provide current income exempted from regular federal income tax by investing in tax-exempt municipal securities that the Fund's investment adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued.

About CELC Celcuity Inc.

Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.

Share on Social Networks: